News & Updates
Filter by Specialty:
Post-ICH antiplatelet therapy not linked to recurrent ICH
28 Oct 2021
byRoshini Claire Anthony
Initiating antiplatelet therapy following an intracerebral haemorrhage (ICH) that occurred during antithrombotic use does not lead to recurrent symptomatic ICH, according to extended results of the RESTART* trial.
Post-ICH antiplatelet therapy not linked to recurrent ICH
28 Oct 2021ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
28 Oct 2021
byJairia Dela Cruz
Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.
ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
28 Oct 2021Modified dual therapy on par with recommended regimen in H. pylori infection
28 Oct 2021
A modified dual therapy as first-line treatment for H. pylori infection demonstrates equal efficacy and compliance relative to recommended regimens, reveals a study. Moreover, a generally modified dual therapy has fewer side effects.